ASHLEIGH GOODWIN: Open Payments
NPI 1336617679 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$962 in 45 payments from 21 companies in 2025. Trend: 2023 $114 · 2024 $1,287 · 2025 $962
Food & beverage: $962
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 9 | $139 |
| Sumitomo Pharma America, Inc. | 5 | $120 |
| Merck Sharp & Dohme LLC | 4 | $109 |
| Janssen Biotech, Inc. | 5 | $94 |
| Dendreon Pharmaceuticals LLC | 2 | $63 |
| Ethicon US, LLC | 3 | $54 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $44 |
| Olympus America Inc. | 2 | $41 |
| Novartis Pharmaceuticals Corporation | 1 | $32 |
| ABBVIE INC. | 1 | $30 |
Products named: Xtandi, ERLEADA, LYNPARZA, PROVENGE, GEMTESA, ORGOVYX, Nubeqa, iTIND System.
Industry payments across TX — which companies pay providers there.
